Article
Kissimmee, Fla. — The time it takes for the U.S. Food and Drug Administration (FDA) approval of a new dermatology drug or treatment depends on many factors, including how closely pharmaceutical companies cooperate with the agency.
Exploring Diagnostic Accuracy and Clinical Reasoning of Dermatological Lesions in Podiatry Students
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Dermatology Times Hosts Inaugural Horizons in Advanced Practice Meeting
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
ICYMI: FDA Greenlights Yesintek, Sixth Biosimilar to Stelara, for Psoriasis and Psoriatic Arthritis
Apogee Announces Clinical Trial Advancements in APG777 for AD Treatment